Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)Sergio Serrano‐Villar, Santiago Moreno, Juan Tiraboschi et al.|Clinical Infectious Diseases|2025Cited by 7